{"title":"The Long-Term Response to Treatment with Calcium Channel Blockers in Patients with Idiopathic Pulmonary Arterial Hypertension.","authors":"Azam Kiani, Razieh Omidvar, Nasim Naderi, Sepideh Taghavi, Marzieh Mirtajaddini","doi":"10.18502/jthc.v18i1.12583","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Long-term outcomes in patients with idiopathic pulmonary arterial hypertension (IPAH) treated with calcium channel blockers (CCBs) are not well documented. Therefore, this study aimed to determine the long-term response to treatment with CCBs in patients with IPAH.</p><p><strong>Methods: </strong>This retrospective cohort study was performed on 81 patients with IPAH admitted to our center. Vasoreactivity testing with adenosine was performed in all patients. Twenty-five patients showed a positive response to vasoreactivity testing and were included in the analysis.</p><p><strong>Results: </strong>Of 24 patients, 20 (83.3%) were female, and the mean age of the patients was 45.90±10.42 years. Fifteen patients improved after 1 year on CCB therapy (the long-term CCB responders group), and 9 showed no improvement (the CCB failure group). The CCB responders group had a greater proportion of patients in New York Heart Association (NYHA) functional class I or II (93.3%), a longer distance walked, and less severe hemodynamic parameters. At the 1-year evaluation, the long-term CCB responders had more improvements in the mean 6-minute walk test result (437.43±125.32 vs 268.17±130.06; P=0.040), the mixed venous oxygen saturation level (71.84±9.87 vs 59.03±9.95; P=0.041), and the cardiac index (4.76±1.12 vs 3.15±0.90; P=0.012). Additionally, mPAP was lower in the long-term CCB responders group (47.35±12.70 vs 67.23±14.08; P=0.034). Finally, all the CCB responders were in NYHA functional class I or II (P=0.001).</p><p><strong>Conclusion: </strong>Our study illustrated that long-term treatment with oral CCBs was effective in 60% of acute responders and 18.5% of the entire study population.</p>","PeriodicalId":39149,"journal":{"name":"Journal of Tehran University Heart Center","volume":"18 1","pages":"62-67"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/d9/JTHC-18-62.PMC10225025.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tehran University Heart Center","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jthc.v18i1.12583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Long-term outcomes in patients with idiopathic pulmonary arterial hypertension (IPAH) treated with calcium channel blockers (CCBs) are not well documented. Therefore, this study aimed to determine the long-term response to treatment with CCBs in patients with IPAH.
Methods: This retrospective cohort study was performed on 81 patients with IPAH admitted to our center. Vasoreactivity testing with adenosine was performed in all patients. Twenty-five patients showed a positive response to vasoreactivity testing and were included in the analysis.
Results: Of 24 patients, 20 (83.3%) were female, and the mean age of the patients was 45.90±10.42 years. Fifteen patients improved after 1 year on CCB therapy (the long-term CCB responders group), and 9 showed no improvement (the CCB failure group). The CCB responders group had a greater proportion of patients in New York Heart Association (NYHA) functional class I or II (93.3%), a longer distance walked, and less severe hemodynamic parameters. At the 1-year evaluation, the long-term CCB responders had more improvements in the mean 6-minute walk test result (437.43±125.32 vs 268.17±130.06; P=0.040), the mixed venous oxygen saturation level (71.84±9.87 vs 59.03±9.95; P=0.041), and the cardiac index (4.76±1.12 vs 3.15±0.90; P=0.012). Additionally, mPAP was lower in the long-term CCB responders group (47.35±12.70 vs 67.23±14.08; P=0.034). Finally, all the CCB responders were in NYHA functional class I or II (P=0.001).
Conclusion: Our study illustrated that long-term treatment with oral CCBs was effective in 60% of acute responders and 18.5% of the entire study population.
背景:特发性肺动脉高压(IPAH)患者接受钙通道阻滞剂(CCBs)治疗的长期预后并没有很好的文献记录。因此,本研究旨在确定IPAH患者对CCBs治疗的长期反应。方法:对81例IPAH患者进行回顾性队列研究。所有患者均行血管反应性腺苷检测。25例患者对血管反应性试验表现出阳性反应,并被纳入分析。结果:24例患者中,女性20例(83.3%),平均年龄45.90±10.42岁。15例患者在CCB治疗1年后改善(长期CCB反应组),9例无改善(CCB失败组)。CCB应答组纽约心脏协会(NYHA)功能等级为I或II级的患者比例更高(93.3%),行走距离更长,血流动力学参数较轻。在1年的评估中,长期CCB应答者在平均6分钟步行测试结果上有更多的改善(437.43±125.32 vs 268.17±130.06;P=0.040),混合静脉氧饱和度(71.84±9.87 vs 59.03±9.95;P=0.041),心脏指数(4.76±1.12 vs 3.15±0.90;P = 0.012)。此外,长期CCB应答组的mPAP较低(47.35±12.70 vs 67.23±14.08;P = 0.034)。最后,所有CCB应答者均处于NYHA功能I或II级(P=0.001)。结论:我们的研究表明,口服CCBs长期治疗对60%的急性应答者和18.5%的整个研究人群有效。